Stock J2AZ34 JAZZ PHARMACEUTICALS PLC
Add to a list
To use this feature you must be a member
Log inSign up

News Jazz Pharmaceuticals plc Sao Paulo

Equities

J2AZ34

BRJ2AZBDR009

Market Closed - Sao Paulo
Other stock markets
 14:17:51 10/05/2024 BST 		5-day change 1st Jan Change
38.72 BRL -0.56% Intraday chart for Jazz Pharmaceuticals plc -.--% -10.95%
06-20 Needham Adjusts Price Target on Jazz Pharmaceuticals to $210 From $222, Maintains Buy Rating MT
06-20 Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Needham Adjusts Price Target on Jazz Pharmaceuticals to $210 From $222, Maintains Buy Rating
MT
Sector Update: Health Care Stocks Lean Lower Pre-Bell Thursday
MT
Sector Update: Health Care
MT
Jazz Pharmaceuticals Says Phase 2b Trial for Suvecaltamide Misses Primary Endpoint -- Shares Slump Pre-Bell
MT
Jazz Pharmaceuticals' tremor drug fails to meet main goal in mid-stage study
RE
Jazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor
PR
Jazz Pharmaceuticals plc Provides Update on Phase 2b Trial of Investigational Suvecaltamide in Essential Tremor
CI
Jazz Pharmaceuticals : 2023 Annual Report
PU
Transcript : Jazz Pharmaceuticals plc Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 10:40 AM
Surging Biotech M&A Reaffirms Massive Opportunity In Rare Disease Drug Development (CRDL,JAZZ, NVO, AZN, SNY)
AQ
Transcript : Jazz Pharmaceuticals plc Presents at Jefferies 2024 Global Healthcare Conference, Jun-06-2024 02:00 PM
Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024
CI
Jazz Pharmaceuticals plc Announces Catherine Sohn, Pharm.D. Will Not Stand for Re-Election to the Board
CI
Jazz Pharmaceuticals plc - Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer
AQ
Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024
PR
Jazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024
CI
Jazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
PR
Sector Update: Health Care Stocks Lean Lower Premarket Wednesday
MT
Jazz Pharmaceuticals Says US FDA Grants Zanidatamab Priority Review to Treat HER2-Positive Metastatic Biliary Tract Cancer
MT
Jazz Pharmaceuticals plc Announces the U.S. Food and Drug Administration Accepted and Granted Priority Review of the Biologics License Application for Zanidatamab
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. JAZZ Stock
  4. J2AZ34 Stock
  5. News Jazz Pharmaceuticals plc